Abstract: High recurrence rates after atrial fibrillation (AF) treatment may be driven by myocardial changes induced by the arrhythmia itself. Understanding the molecular mechanisms behind these changes is crucial for developing targeted therapies and improving outcomes. Objective: To characterise the cardiac transcriptome of healthy horses and explore transcriptional changes associated with persistent AF (naturally occurring and tachypacing-induced). Methods: Case-control study. Methods: RNA-sequencing was performed on atrial and ventricular tissue samples collected from six horses with naturally occurring persistent AF (lasting 2-12 weeks) and six healthy controls. Differential gene expression and pathway enrichment analyses were conducted to identify chamber-specific differences and molecular pathways associated with AF. Findings were integrated with proteomic data and compared with transcriptional changes in a separate cohort of 10 horses with tachypacing-induced AF. Atrial metabolic remodelling was further investigated by evaluating the activity of AMP-activated protein kinase (AMPK), a central metabolic regulator and measuring local glycogen content. Results: The transcriptomes of the four heart chambers had distinct molecular identities. Expression of ion channels and genes encoding calcium handling proteins was largely similar to humans, despite important differences in the ventricular expression of repolarising potassium channels. Persistent AF was associated with minimal ion channel changes but significant upregulation of metabolic, fibrotic and myofibrillar pathways. Metabolic remodeling included upregulation of fatty acid and glycolytic pathways, increased glycogen content in the left atrium and preserved AMPK activity in the right atrium. Transcriptomic profiles of naturally occurring persistent AF correlated well with those of tachypacing-induced AF. Conclusions: The study cannot distinguish changes predisposing to AF from those caused by it. Conclusions: Persistent AF was associated with changes in metabolic and fibrotic pathways in the atria, with minimal ion channel remodeling. Targeting these pathways, rather than focusing solely on the electrical disturbance, may improve treatment outcomes in equine AF.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
Overview
This study analyzed the heart tissue gene expression (transcriptome) of healthy horses and horses with persistent atrial fibrillation (AF) to understand the molecular changes associated with AF.
The research identified significant metabolic and fibrotic pathway alterations in the atria of horses with persistent AF, suggesting new targets for treatment beyond electrical abnormalities.
Background
Atrial fibrillation (AF) is a common heart rhythm disorder with high rates of recurrence after treatment.
Recurrent AF may be driven by structural and molecular changes in the heart muscle caused by the arrhythmia itself.
Understanding these underlying molecular changes is vital for developing better, more targeted therapies.
Horses serve as an important large animal model for AF due to similarities with human heart physiology.
Objectives
Characterize the cardiac transcriptome (gene expression profile) of healthy horses to establish baseline molecular signatures of different heart chambers.
Identify changes in gene expression associated with persistent AF, both naturally occurring and artificially induced by tachypacing.
Investigate metabolic remodeling in AF by studying pathways related to fatty acid and glucose metabolism, as well as activity of AMP-activated protein kinase (AMPK).
Methods
Conducted a case-control study with 6 horses having naturally occurring persistent AF (2-12 weeks duration) and 6 healthy controls.
Collected tissue samples from all four heart chambers (atria and ventricles) to perform RNA-sequencing for transcriptomic profiling.
Performed differential gene expression analyses to identify chamber-specific molecular differences and pathways altered by AF.
Integrated transcriptomic data with proteomics to validate key molecular findings.
Compared natural persistent AF profiles with data from a separate group of 10 horses having tachypacing-induced AF to assess consistency of changes.
Assessed metabolic remodeling by measuring AMPK activity and glycogen content in atrial tissues, reflecting energy metabolism changes.
Key Findings
Each heart chamber had a distinct transcriptomic signature, indicating unique molecular identities within the heart.
Gene expression of ion channels and calcium handling proteins in horses closely resembled human hearts, but with notable differences in ventricular potassium channel expression involved in repolarization.
Persistent AF caused minimal changes in ion channel gene expression, suggesting electrical remodeling was limited.
Significant upregulation was observed in metabolic genes, fibrotic pathways (related to tissue scarring), and myofibrillar components in the atria during AF.
Metabolic remodeling included increased expression of genes involved in fatty acid metabolism and glycolysis, indicating altered energy usage in AF.
Left atrial tissue of AF horses showed greater glycogen storage, and right atrial tissue maintained AMPK activity, a key regulator of cellular energy homeostasis.
The transcriptional changes in naturally occurring AF showed strong correlation with those from tachypacing-induced AF, supporting model validity.
Interpretation
The study highlights that AF-associated remodeling in horses primarily affects metabolic and fibrotic pathways rather than ion channel expression.
These findings suggest that recurring AF may perpetuate and worsen by changing the heart’s metabolism and structure rather than just altering electrical properties.
Since changes predisposing to AF cannot be clearly distinguished from those caused by AF itself, this cross-sectional study cannot establish causality.
The similarity between natural and induced AF transcriptomes supports the use of tachypacing models for future research.
Implications and Future Directions
The minimal electrical remodeling observed shifts focus toward metabolic and fibrotic pathways as potential therapeutic targets in equine AF.
Targeting metabolic alterations (e.g., fatty acid/glycolytic pathways, AMPK modulation) and fibrosis could improve treatment outcomes beyond current strategies that mainly address electrical disturbances.
Further longitudinal studies are needed to differentiate molecular changes that lead to AF from those that result from AF.
Understanding species-specific differences in ion channel expression can inform translational relevance to human AF research.
Cite This Article
APA
Haugaard SL, Nissen SD, Schneider MJ, Birk JB, Carstensen H, Hopster-Iversen C, Altıntaş A, Barrès R, Kjøbsted R, Wojtaszewski JFP, Herum KM, Jespersen T, Buhl R.
(2025).
The horse cardiac transcriptome: Moving towards a molecular understanding of atrial fibrillation.
Equine Vet J.
https://doi.org/10.1111/evj.70115
Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Nissen, Sarah Dalgas
Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Cardiac Physiology Laboratory, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Schneider, Mélodie Jil
Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Birk, Jesper Bratz
August Krogh Section for Human and Molecular Physiology, Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
Carstensen, Helena
Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Hopster-Iversen, Charlotte
Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Altıntaş, Ali
Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Barrès, Romain
Novo Nordisk Foundation Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Kjøbsted, Rasmus
August Krogh Section for Human and Molecular Physiology, Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
Wojtaszewski, Jørgen F P
August Krogh Section for Human and Molecular Physiology, Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
Herum, Kate M
Research and Early Development, Novo Nordisk A/S, Måløv, Denmark.
Jespersen, Thomas
Cardiac Physiology Laboratory, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Buhl, Rikke
Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Nattel S, Heijman J, Zhou L, Dobrev D. Molecular basis of atrial fibrillation pathophysiology and therapy: a translational perspective. Circ Res 2020;127:51–72.
Harada M, Melka J, Sobue Y, Nattel S. Metabolic considerations in atrial fibrillation – mechanistic insights and therapeutic opportunities. Circ J 2017;81:1749–1757.
McCauley MD, Iacobellis G, Li N, Nattel S, Goldberger JJ. Targeting the substrate for atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol 2024;83:2015–2027.
Darkow E, Nguyen TT, Stolina M, Kari FA, Schmidt C, Wiedmann F. Small conductance Ca2+‐activated K+ (SK) channel mRNA expression in human atrial and ventricular tissue: comparison between donor, atrial fibrillation and heart failure tissue. Front Physiol 2021;12:650964.
Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014;30:923–930.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W. Limma powers differential expression analyses for RNA‐sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.
Bastian FB, Roux J, Niknejad A, Comte A, Fonseca Costa SS, de Farias TM. The Bgee suite: integrated curated expression atlas and comparative transcriptomics in animals.. Nucleic Acids Res 2021;49:D831–D847.
Marchiano F, Haering M, Habermann BH. The mitoXplorer 2.0 update: integrating and interpreting mitochondrial expression dynamics within a cellular context.. Nucleic Acids Res 2022;50:W490–W499.
Harada M, Tadevosyan A, Qi X, Xiao J, Liu T, Voigt N. Atrial fibrillation activates AMP‐dependent protein kinase and its regulation of cellular calcium handling: potential role in metabolic adaptation and prevention of progression.. J Am Coll Cardiol 2015;66:47–58.
Birk JB, Wojtaszewski JFP. Kinase activity determination of specific AMPK complexes/heterotrimers in the skeletal muscle.. AMPK. Methods in Molecular Biology 2018.
Passonneau JV, Lowry OH. A collection of enzyme assays.. Enzymatic analysis: a practical guide 1993;p. 229–305.
Bernal‐Ramirez J, Díaz‐Vesga MC, Talamilla M, Méndez A, Quiroga C, Garza‐Cervantes JA. Exploring functional differences between the right and left ventricles to better understand right ventricular dysfunction.. Oxid Med Cell Longev 2021;2021:9993060.
Borg TK, Sullivan T, Ivy J. Functional arrangement of connective tissue in striated muscle with emphasis on cardiac muscle.. Scan Electron Microsc 1982;1775–1784.
Koenig AL, Shchukina I, Amrute J, Andhey PS, Zaitsev K, Lai L. Single‐cell transcriptomics reveals cell‐type‐specific diversification in human heart failure.. Nat Cardiovasc Res 2022;1:263–280.
Walklate J, Ferrantini C, Johnson CA, Tesi C, Poggesi C, Geeves MA. Alpha and beta myosin isoforms and human atrial and ventricular contraction.. Cell Mol Life Sci 2021;78:7309–7337.
Gaborit N, le Bouter S, Szuts V, Varro A, Escande D, Nattel S. Regional and tissue specific transcript signatures of ion channel genes in the non‐diseased human heart.. J Physiol 2007;582:675–693.
Niwa N, Nerbonne JM. Molecular determinants of cardiac transient outward potassium current (I(to)) expression and regulation.. J Mol Cell Cardiol 2010;48:12–25.
Finley MR, Lillich JD, Gilmour RF Jr, Freeman LC. Structural and functional basis for the long QT syndrome: relevance to veterinary patients.. J Vet Intern Med 2003;17:473–488.
Pedersen PJ, Thomsen KB, Flak JB, Tejada MA, Hauser F, Trachsel D. Molecular cloning and functional expression of the K(+) channel K(V)7.1 and the regulatory subunit KCNE1 from equine myocardium.. Res Vet Sci 2017;113:79–86.
Pedersen PJ, Thomsen KB, Olander ER, Hauser F, Tejada MA, Poulsen KL. Molecular cloning and functional expression of the equine K+ channel KV11.1 (ether a go‐go‐related/KCNH2 gene) and the regulatory subunit KCNE2 from equine myocardium.. PLoS One 2015;10:e0138320.
Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T. The G protein–gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation.. Circulation 2005;112:3697–3706.
Fenner MF, Carstensen H, Dalgas Nissen S, Melis Hesselkilde E, Scott Lunddahl C, Adler Hess Jensen M. Effect of selective I(K,ACh) inhibition by XAF‐1407 in an equine model of tachypacing‐induced persistent atrial fibrillation.. Br J Pharmacol 2020;177:3778–3794.
Wiedmann F, Beyersdorf C, Zhou XB, Kraft M, Paasche A, Jávorszky N. Treatment of atrial fibrillation with doxapram: TASK‐1 potassium channel inhibition as a novel pharmacological strategy.. Cardiovasc Res 2022;118:1728–1741.
Wiedmann F, Beyersdorf C, Zhou XB, Kraft M, Foerster KI, el‐Battrawy I. The experimental TASK‐1 potassium channel inhibitor A293 can be employed for rhythm control of persistent atrial fibrillation in a translational large animal model.. Front Physiol 2021;11:629421.
Verhaeghe LM. Proceedings of the 2024 ECEIM congress.. 2024.
Schmidt C, Wiedmann F, Voigt N, Zhou XB, Heijman J, Lang S. Upregulation of K(2P)3.1 K+ current causes action potential shortening in patients with chronic atrial fibrillation.. Circulation 2015;132:82–92.
Tribulova N, Egan Benova T, Szeiffova Bacova B, Viczenczova C, Barancik M. New aspects of pathogenesis of atrial fibrillation: remodelling of intercalated discs.. J Physiol Pharmacol 2015;66:625–634.
Olesen MS, Bentzen BH, Nielsen JB, Steffensen AB, David JP, Jabbari J. Mutations in the potassium channel subunit KCNE1 are associated with early‐onset familial atrial fibrillation.. BMC Med Genet 2012;13:24.
Yang Q, Xie Z, Lai B, Cheng G, Liao B, Wan J. Identification and verification of atrial fibrillation hub genes caused by primary mitral regurgitation.. Medicine 2023;102:e35851.
Crespo‐Garcia T, Cámara‐Checa A, Dago M, Rubio‐Alarcón M, Rapún J, Tamargo J. Regulation of cardiac ion channels by transcription factors: looking for new opportunities of druggable targets for the treatment of arrhythmias.. Biochem Pharmacol 2022;204:115206.
Burnicka‐Turek O, Broman MT, Steimle JD, Boukens BJ, Petrenko NB, Ikegami K. Transcriptional patterning of the ventricular cardiac conduction system.. Circ Res 2020;127:e94–e106.
Ji J‐J, Qian LL, Zhu Y, Jiang Y, Guo JQ, Wu Y. Kallistatin/Serpina3c inhibits cardiac fibrosis after myocardial infarction by regulating glycolysis via Nr4a1 activation.. Biochim Biophys Acta Mol Basis Dis 2022;1868:166441.
Ma Y‐L, Kong CY, Guo Z, Wang MY, Wang P, Liu FY. Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5/NR4a1 axis.. Nat Commun 2024;15:4757.
Kharlap MS, Timofeeva AV, Goryunova LE, Khaspekov GL, Dzemeshkevich SL, Ruskin VV. Atrial appendage transcriptional profile in patients with atrial fibrillation with structural heart diseases.. Ann N Y Acad Sci 2006;1091:205–217.
Chilukoti RK, Giese A, Malenke W, Homuth G, Bukowska A, Goette A. Atrial fibrillation and rapid acute pacing regulate adipocyte/adipositas‐related gene expression in the atria.. Int J Cardiol 2015;187:604–613.
Peng H, Yuan J, Wang Z, Mo B, Wang Y, Wang Y. NR4A3 prevents diabetes induced atrial cardiomyopathy by maintaining mitochondrial energy metabolism and reducing oxidative stress.. EBioMedicine 2024;106:105268.
Dobrev D, Heijman J, Hiram R, Li N, Nattel S. Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology.. Nat Rev Cardiol 2023;20:145–167.
Barth AS, Merk S, Arnoldi E, Zwermann L, Kloos P, Gebauer M. Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular‐like genomic signature.. Circ Res 2005;96:1022–1029.
Vigil‐Garcia M, Demkes CJ, Eding JEC, Versteeg D, de Ruiter H, Perini I. Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodelling.. Cardiovasc Res 2021;117:1532–1545.
Tu T, Zhou S, Liu Z, Li X, Liu Q. Quantitative proteomics of changes in energy metabolism‐related proteins in atrial tissue from valvular disease patients with permanent atrial fibrillation. Circ J 2014;78:993–1001.
Corradi D, Callegari S, Benussi S, Maestri R, Pastori P, Nascimbene S. Myocyte changes and their left atrial distribution in patients with chronic atrial fibrillation related to mitral valve disease. Hum Pathol 2005;36:1080–1089.
Chakraborty P, Nattel S, Nanthakumar K. Linking cellular energy state to atrial fibrillation pathogenesis: potential role of adenosine monophosphate‐activated protein kinase. Heart Rhythm 2020;17:1398–1404.
van den Berg NWE, Neefs J, Kawasaki M, Nariswari FA, Wesselink R, Fabrizi B. Extracellular matrix remodeling precedes atrial fibrillation: results of the PREDICT‐AF trial. Heart Rhythm 2021;18:2115–2125.